GALVANIZE
10.3.2020 14:02:15 CET | Business Wire | Press release
Galvanize , the leader in SaaS governance, risk, and compliance (GRC) software, is pleased to announce that it has been named a Leader in The Forrester Wave™: Governance, Risk, and Compliance Software, Q1 2020.
Galvanize received the top scores possible in the risk and control management, document management, audit management, and IT risk management criteria. In addition, the company was among the top ranked in the criteria of advanced predictive analytics, which is defined as “superior capabilities relative to others in the evaluation, including AI and ML capability to support advanced modelling in Python and R, advanced anomaly detection, and continuous auditing.”
“We’re extremely proud to be named as a Leader in Forrester’s rigorous evaluation system,” said Dan Zitting, chief product & strategy officer, Galvanize. “We believe this accomplishment is a testament to the hard work of marrying our GRC platforms to create an end-to-end system that sets the industry standard for stronger IT security, risk management, compliance, and assurance.”
The report notes the company’s successful integration of ACL and Rsam to create a combined industry catalyst. According to the report, the HighBond platform, which has achieved FedRAMP Moderate authorization, “combines Rsam’s aptitude for collecting and operationalizing data with ACL’s powerful analytics and robotic process automation, enabling GRC pros to capitalize on digital transformation”. The report explains: “Notwithstanding the sophistication, customers enjoy managing the platform themselves and appreciate Client Partners, the vendor’s unique take on customer success that combines guidance, best practices, and access to other customers to help solve similar problems.”
“We’re witnessing a shift among the world’s most influential businesses, as they demand value from organizations that stretch beyond financial profit,” said Laurie Schultz, president & CEO, Galvanize. “Being recognized as a Leader by Forrester is extremely impactful, as it corroborates our unique vision to create a comprehensive GRC offering worthy of tomorrow’s workforce, as well as bringing us closer to our goal of consolidating the GRC industry, and being the operating system for conscious organizations.”
The Forrester Wave™ is one of the industry’s most complete and detailed analyses, using a transparent methodology composed of vendor surveys, product demos, and customer reference calls to compare top players in the market. This latest recognition builds on a long history of industry recognition among leading analyst firms for Galvanize. The company was named a Leader in Gartner Magic Quadrant for IT Vendor Risk Management Tools in December 2019 and a Leader in Gartner Magic Quadrant for IT Risk Management in July 2019.
A full, complimentary version of the report, The Forrester Wave™: Governance, Risk, and Compliance Software, Q1 2020 is available for download from Galvanize at: https://info.wegalvanize.com/forrester-wave-grc-platforms-2020-report.html
To learn more about Galvanize and its comprehensive GRC platform, visit: wegalvanize.com .
About Galvanize:
Galvanize builds award-winning, cloud-based security, risk management, compliance, and audit software to drive change in some of the world’s largest organizations. We’re on a mission to unite and strengthen individuals and entire organizations through the integrated HighBond software platform. With more than 6,300 customer organizations in 130 countries, Galvanize is connecting teams in many of the Fortune 1,000 and S&P 500 companies, and hundreds of government organizations, banks, manufacturers, and healthcare organizations. Whether these professionals are managing threats, assessing risk, measuring controls, monitoring compliance, or expanding assurance coverage, HighBond automates manual tasks, blends organization-wide data, and broadcasts it in easy-to-share dashboards and reports. But we don’t just make technology—we provide tools that inspire individuals to achieve great things and do heroic work in the process.
Supporting Resources:
Website: www.wegalvanize.com
Twitter: https://twitter.com/wegalvanize
LinkedIn: https://linkedin.com/company/wegalvanize
©2020 ACL Services Ltd. ACL, Galvanize, the Galvanize logo, HighBond, and the HighBond logo are trademarks or registered trademarks of ACL Services Ltd. dba Galvanize. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200310005234/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom